Innate Pharma SA (IPHA) Form 6-K — Oct 27, 2026
Innate Pharma announced that AstraZeneca has pushed the expected high-level data readout of the PACIFIC-9 Phase 3 trial to the first half of 2027, from the second half of 2026 previously. The company attributed the shift to the event-driven nature of the study, and noted that enrollment in the trial is complete. PACIFIC-9, led by AstraZeneca, tests durvalumab combined with monalizumab or oleclumab in unresectable Stage III non-small cell lung cancer patients who have not progressed after platinum-based chemoradiation. Monalizumab is Innate's anti-NKG2A antibody, with AstraZeneca holding full oncology rights under their collaboration since October 2018.
Key figures
- New readout window
- H1 2027
- Prior readout window
- H2 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.